More

    Japan Approves COVAXIN booster dose for Travelers; reinforces the effectiveness of Universal Covid Vaccine

    Japan on Friday accorded approval for Bharat Biotech’s Covaxin booster dose for travellers. In April this year, the nation included the Made-in-India Covid-19 vaccine in the list of recognised vaccines. And, now (August 5), Japan has also approved the booster shot of Covaxin.

    Bharat Biotech wrote in a statement, “We are proud to announce, Japan has approved COVAXIN booster dose for travellers”.

    Earlier this month, the vaccine developer announced that the administration of the third dose of its Covid-19 vaccine Covaxin (BBV152) after six months of two-dose vaccination significantly enhanced neutralizing antibody responses, and demonstrated increased memory B cell response in subjects in controlled clinical trials.

    The findings published in a peer review journals were based on a comprehensive study that has demonstrated multiple benefits of Covaxin. According to Bharat Biotech the vaccine provides benefits like long-term immune response, cell-mediated immunity, the safety of booster dose, and immunogenicity against spike protein.

    The biotech major also said immune responses declined at six months but increased by 40-fold in subjects who received a booster dose. Immune responses when assessed against variants of concern and persisted up to 12 months.

    Covaxin is a multi-epitome vaccine – Dr. Krishna Ella

    Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech, said, “Our team has now demonstrated that Covaxin is a multi-epitope vaccine with antibodies against spike, RBD, and N proteins. Post booster dose, it has proven to neutralize antibody responses against variants of concern and long-term protection through memory T and B cell responses. We have now achieved our goal of developing a safe and efficacious vaccine with long-term protection against a spectrum of variants.”

    The study was conducted on 184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, 6 months after the primary series of two doses. Subjects were evaluated for safety, neutralizing antibody responses against variants of concern, binding antibodies against spike protein, RBD, and N proteins, and for memory T and B cell responses to demonstrate cell-mediated immunity, said the company.

    Share

    Latest Updates

    Related Articles

    WHO Sounds Alarm: Disease X Poses New Global Pandemic Threat

    Disease X seem to be the new potential Pandemic. Concerns over this mysterious disease...

    Evergreen Dev Anand, Continue to Influence generations, and PM Modi

    Dev Anand Ji is remembered as an evergreen icon. His flair for storytelling and...

    Taylor Swift and Travis Kelce Sparks Fresh Rumors at the Chiefs Game

    Pop superstar Taylor Swift and NFL star Travis Kelce were seen together at the...

    Google Pixel 8, Pixel 8 Pro: Price vs Major Upgrades

    Google Pixel 8 and Google Pixel 8 Pro Update: As Google is set to...